Welcome to CDC stacks | Continuing Effectiveness of Serogroup A Meningococcal Conjugate Vaccine, Chad, 2013 - 26666 | Emerging Infectious Diseases
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Continuing Effectiveness of Serogroup A Meningococcal Conjugate Vaccine, Chad, 2013
Filetype[PDF-498.63 KB]


Details:
No Related Documents.
You May Also Like:
  1. Public Health Impact After the Introduction of PsA-TT: The First 4 Years
    Personal Author:
    Diomandé, Fabien V. K.; Djingarey, Mamoudou H.; Daugla, Doumagoum M.; Novak, Ryan T.; Kristiansen, Paul A.; Collard, Jean-Marc; Gamougam, Kadidja; Kandolo, Denis; Mbakuliyemo, Nehemie; Mayer, Leonard; Stuart, James; Clark, Thomas; Tevi-Benissan, Carol; Perea, William A.; Preziosi, Marie-Pierre; Marc LaForce, F.; Caugant, Dominique; Messonnier, Nancy; Walker, Oladapo; Greenwood, Brian;
    Published:
    Nov 15 2015
    Source:
    Clin Infect Dis. 2015; 61(Suppl 5):S467-S472.
    Description:
    During the first introduction of a group A meningococcal vaccine (PsA-TT) in 2010-2011 and its rollout from 2011 to 2013, >150 million eligible people, representing 12 hyperendemic meningitis countries, have been vaccinated.|The new vaccine effective...
    File Type:
    Filetype[PDF - 175.59 KB]
  2. MMWR. Morbidity and mortality weekly report, Vol. 64, no. 41, October 23, 2015
    Corporate Author:
    Centers for Disease Control and Prevention (U.S.)
    Published:
    October 23, 2015
    Series:
    MMWR. Morbidity and mortality weekly report ; v. 64, no. 41
    Description:
    Progress Toward Global Eradication of Dracunculiasis, January 2014–June 2015 -- Progress Toward Poliomyelitis Eradication — Afghanistan, January 2014–August 2015 -- Use of Serogroup B Meningococcal Vaccines in Adolescents and Young Adults: Reco...
    File Type:
    Filetype[PDF - 1.16 MB]
  3. Introduction and Rollout of a New Group A Meningococcal Conjugate Vaccine (PsA-TT) in African Meningitis Belt Countries, 2010–2014
    Personal Author:
    Djingarey, Mamoudou H.; Diomandé, Fabien V. K.; Barry, Rodrigue; Kandolo, Denis; Shirehwa, Florence; Lingani, Clement; Novak, Ryan T.; Tevi-Benissan, Carol; Perea, William; Preziosi, Marie-Pierre; LaForce, F. Marc;
    Published:
    Nov 15 2015
    Source:
    Clin Infect Dis. 2015; 61(Suppl 5):S434-S441.
    Description:
    A group A meningococcal conjugate vaccine (PsA-TT) was developed specifically for the African "meningitis belt" and was prequalified by the World Health Organization (WHO) in June 2010. The vaccine was first used widely in Burkina Faso, Mali, and Nig...
    File Type:
    Filetype[PDF - 347.17 KB]
  4. DBD bulletin ; issue 11, summer 2012
    Corporate Author:
    National Center for Immunization and Respiratory Diseases (U.S.). Division of Bacterial Diseases.
    Published:
    summer 2012
    Series:
    DBD bulletin ; issue 11
    Description:
    The Active Bacterial Core surveillance -- Meningitis in Sub-Saharan Africa -- Reducing Pneumonia -- OD News and Staff Notes -- Vaccine News -- Communications -- Featured Publications.
    File Type:
    Filetype[PDF - 1.90 MB]
  5. Molecular Characterization of Invasive Meningococcal Isolates from Countries in the African Meningitis Belt before Introduction of a Serogroup A Conjugate Vaccine
    Personal Author:
    Caugant, Dominique A.; Kristiansen, Paul A.; Wang, Xin; Mayer, Leonard W.; Taha, Muhamed-Kheir; Ouédraogo, Rasmata; Kandolo, Denis; Bougoudogo, Flabou; Sow, Samba; Bonte, Laurence;
    Published:
    Sep 27 2012
    Source:
    PLoS One. 7(9).
    Description:
    Background : The serogroup A conjugate meningococcal vaccine, MenAfriVac, was introduced in mass vaccination campaigns in December 2010 in Burkina Faso, Mali and Niger. In the coming years, vaccination will be extended to other African countries at r...
    File Type:
    Filetype[PDF - 256.13 KB]